734 related articles for article (PubMed ID: 29781586)
1. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
2. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.
Walker KM; Pope J; ;
Semin Arthritis Rheum; 2012 Aug; 42(1):42-55. PubMed ID: 22464314
[TBL] [Abstract][Full Text] [Related]
3. Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O; Fransen J; Avouac J; Becker M; Kulak A; Allanore Y; Distler O; Clements P; Cutolo M; Czirjak L; Damjanov N; Del Galdo F; Denton CP; Distler JHW; Foeldvari I; Figelstone K; Frerix M; Furst DE; Guiducci S; Hunzelmann N; Khanna D; Matucci-Cerinic M; Herrick AL; van den Hoogen F; van Laar JM; Riemekasten G; Silver R; Smith V; Sulli A; Tarner I; Tyndall A; Welling J; Wigley F; Valentini G; Walker UA; Zulian F; Müller-Ladner U;
Ann Rheum Dis; 2017 Aug; 76(8):1327-1339. PubMed ID: 27941129
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort.
Windirsch K; Jordan S; Becker MO; Bruni C; Dobrota R; Elhai M; Garaiman IA; Mihai CM; Iudici M; Hasler P; Ribi C; Maurer B; Gabrielli A; Hoffmann-Vold AM; Distler O
Swiss Med Wkly; 2024 Feb; 154():3630. PubMed ID: 38579324
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
6. State-of-the-art evidence in the treatment of systemic sclerosis.
Pope JE; Denton CP; Johnson SR; Fernandez-Codina A; Hudson M; Nevskaya T
Nat Rev Rheumatol; 2023 Apr; 19(4):212-226. PubMed ID: 36849541
[TBL] [Abstract][Full Text] [Related]
7. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
9. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension.
Opitz C; Klein-Weigel PF; Riemekasten G
Vasa; 2011 Jan; 40(1):20-30. PubMed ID: 21283970
[TBL] [Abstract][Full Text] [Related]
10. [Management of patients with systemic sclerosis].
Wiesik-Szewczyk E; Olesińska M
Pol Merkur Lekarski; 2010 May; 28(167):421-3. PubMed ID: 20568411
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
[TBL] [Abstract][Full Text] [Related]
13. Treatment Algorithms in Systemic Lupus Erythematosus.
Muangchan C; van Vollenhoven RF; Bernatsky SR; Smith CD; Hudson M; Inanç M; Rothfield NF; Nash PT; Furie RA; Senécal JL; Chandran V; Burgos-Vargas R; Ramsey-Goldman R; Pope JE
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1237-1245. PubMed ID: 25777803
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
Vanthuyne M; Blockmans D; Westhovens R; Roufosse F; Cogan E; Coche E; Nzeusseu Toukap A; Depresseux G; Houssiau FA
Clin Exp Rheumatol; 2007; 25(2):287-92. PubMed ID: 17543155
[TBL] [Abstract][Full Text] [Related]
16. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.
Moinzadeh P; Riemekasten G; Siegert E; Fierlbeck G; Henes J; Blank N; Melchers I; Mueller-Ladner U; Frerix M; Kreuter A; Tigges C; Lahner N; Susok L; Guenther C; Zeidler G; Pfeiffer C; Worm M; Karrer S; Aberer E; Bretterklieber A; Genth E; Simon JC; Distler JH; Hein R; Schneider M; Seitz CS; Herink C; Steinbrink K; Sárdy M; Varga R; Mensing H; Mensing C; Lehmann P; Neeck G; Fiehn C; Weber M; Goebeler M; Burkhardt H; Buslau M; Ahmadi-Simab K; Himsel A; Juche A; Koetter I; Kuhn A; Sticherling M; Hellmich M; Kuhr K; Krieg T; Ehrchen J; Sunderkoetter C; Hunzelmann N;
J Rheumatol; 2016 Jan; 43(1):66-74. PubMed ID: 26568599
[TBL] [Abstract][Full Text] [Related]
18. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
